Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 2,500 shares at $12.95 ($32K) on 2026-04-01, disclosed to the SEC on 2026-04-02.
Scheduled sale ($32k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |
| TRDA | SELL | 2024-12-03 | $120K | — | Filing → |